Ferro Corp. (FOE) said that Benjamin Schlater, who has served as Ferro’s Vice President, Corporate Development and Strategy since September 2015, has been named Vice President and Chief Financial Officer, succeeding Jeffrey Rutherford, who stepped down from the position on September 1.
James Barna, Ferro’s Corporate Controller, has been appointed to the additional role of Chief Accounting Officer of the Company.
Lori Saviers, who was Ferro’s Chief Procurement Officer, has been named Vice President, Sourcing and Global Supply Chain. In addition, Sandy Frydryk has been named Director, Corporate Development and Integration.
Rutherford is expected to remain with the Company as an advisor to Schlater through the end of 2016 to ensure a smooth transition of responsibilities.
Schlater joined Ferro in September 2015. He has nearly 20 years of corporate finance experience. His experience includes serving as treasurer and head of corporate development, strategic and financial planning, and risk management at Veyance Technologies, a $2 billion global manufacturing company then owned by The Carlyle Group. Prior to Veyance, he was a managing director at FTI Consulting. Prior to that, he was a manager at PricewaterhouseCoopers in its corporate finance practice.
Source: RTT News
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
